INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 201 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 1.09 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $6,741,000 | +86.7% | 54,400 | 0.0% | 0.21% | +47.9% |
| Q3 2019 | $3,610,000 | -9.3% | 54,400 | +8.8% | 0.14% | 0.0% |
| Q2 2019 | $3,979,000 | +178.8% | 50,000 | +400.0% | 0.14% | +35.8% |
| Q2 2016 | $1,427,000 | +11.1% | 10,000 | 0.0% | 0.11% | -1.9% |
| Q1 2016 | $1,285,000 | -44.5% | 10,000 | -35.5% | 0.11% | -38.3% |
| Q4 2015 | $2,315,000 | -57.1% | 15,500 | -52.3% | 0.18% | -60.0% |
| Q3 2015 | $5,390,000 | -31.3% | 32,500 | 0.0% | 0.44% | -23.6% |
| Q2 2015 | $7,845,000 | -22.7% | 32,500 | -9.7% | 0.57% | -39.7% |
| Q1 2015 | $10,153,000 | +296.9% | 36,000 | +119.5% | 0.95% | +217.7% |
| Q4 2014 | $2,558,000 | -28.4% | 16,400 | +8.6% | 0.30% | -45.9% |
| Q3 2014 | $3,574,000 | +0.0% | 15,100 | 0.0% | 0.55% | -13.7% |
| Q2 2014 | $3,573,000 | -16.7% | 15,100 | +16.2% | 0.64% | -35.2% |
| Q1 2014 | $4,287,000 | +280.4% | 13,000 | -21.2% | 0.99% | +145.4% |
| Q4 2013 | $1,127,000 | – | 16,500 | – | 0.40% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |